Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease

NCT00035308 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunologic Diseases
Autoimmune Diseases
Systemic Lupus Erythematosus
Lupus Nephritis
Lupus Glomerulonephritis

Interventions

DRUG: Abetimus sodium (LJP 394)

Sponsor

La Jolla Pharmaceutical Company